Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Synvisc
|
| gptkbp:activities |
reduces friction
provides lubrication |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Hyalgan
|
| gptkbp:clinical_trial |
Phase III
Long-term effects Efficacy in knee osteoarthritis Safety profile in elderly patients hip osteoarthritis knee osteoarthritis shoulder osteoarthritis |
| gptkbp:contraindication |
infection at injection site
hypersensitivity to hyaluronate |
| gptkbp:dosage_form |
gptkb:software_framework
|
| gptkbp:duration |
3 to 5 weeks
|
| gptkbp:formulation |
viscosupplement
|
| gptkbp:frequency |
once a week
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hyalgan
|
| gptkbp:indication |
pain relief
improving joint function |
| gptkbp:ingredients |
sodium hyaluronate
|
| gptkbp:invention |
patented
|
| gptkbp:is_used_for |
osteoarthritis
|
| gptkbp:manager |
injection
intra-articular injection |
| gptkbp:manufacturer |
Fidia Farmaceutici
|
| gptkbp:marketed_as |
gptkb:Europe
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
single-dose vials
|
| gptkbp:pharmacokinetics |
local action
minimal systemic absorption |
| gptkbp:population |
adults
elderly |
| gptkbp:previous_name |
sodium hyaluronate
|
| gptkbp:provides_information_on |
gptkb:American_Academy_of_Orthopaedic_Surgeons
European Society of Musculoskeletal Radiology |
| gptkbp:regulatory_compliance |
gptkb:CE_mark
Health Canada approval |
| gptkbp:side_effect |
dizziness
headache nausea swelling joint pain injection site reactions |
| gptkbp:storage |
room temperature
|
| gptkbp:treatment |
enhance quality of life
improve mobility patient satisfaction reduce pain improved function pain reduction |